543 is the total number of securities SECTORAL ASSET MANAGEMENT INC has owned. The longest SECTORAL ASSET MANAGEMENT INC has owned a single stock is 42 quarters.
| Period | Weighting | Quarter | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
| BMRN | BIOMARIN PHARMAC INC | 42 | 42 | 0.14% | 2.77% | 6.67% | Q2 2013 | Q3 2023 | 42 |
| PTCT | PTC THERAPEUTICS INC | 42 | 42 | 0.04% | 1.41% | 2.69% | Q2 2013 | Q3 2023 | 42 |
| RDY | DR REDDYS LABS LTD | 42 | 42 | 0.03% | 0.33% | 2.01% | Q2 2013 | Q3 2023 | 42 |
| GILD | GILEAD SCIENCES INC | 23 | 1 | 0.12% | 2.87% | 8.35% | Q2 2013 | Q3 2023 | 38 |
| INCY | INCYTE CORPORATION | 22 | 16 | 0.05% | 1.59% | 5.21% | Q2 2013 | Q3 2023 | 38 |
| VRTX | VERTEX PHARMACEUTICL | 21 | 3 | 0.15% | 1.51% | 5.98% | Q2 2013 | Q3 2023 | 38 |
| FOLD | AMICUS THERAPEUTICS INC | 37 | 37 | 0.05% | 3.06% | 6.56% | Q3 2014 | Q3 2023 | 37 |
| PFE | PFIZER INC | 15 | 1 | 0.22% | 2.09% | 6.35% | Q3 2013 | Q3 2023 | 35 |
| MRK | MERCK & CO. INC | 11 | 5 | 0.26% | 2.01% | 6.35% | Q2 2013 | Q3 2023 | 34 |
| MDT | MEDTRONIC PLC | 26 | 7 | 0.32% | 1.31% | 4.42% | Q1 2015 | Q3 2023 | 33 |
| BIIB | BIOGEN INC | 16 | 2 | 0.06% | 2.69% | 8.36% | Q2 2013 | Q3 2023 | 32 |
| REGN | REGENERON PHARMCTICALS | 15 | 1 | 0.06% | 1.74% | 5.47% | Q2 2013 | Q3 2023 | 31 |
| TMO | THERMO FISHER SCIENTIF... | 13 | 6 | 0.12% | 1.49% | 3.88% | Q2 2013 | Q3 2023 | 31 |
| LLY | LILLY ELI & CO | 24 | 1 | 0.46% | 1.67% | 5.94% | Q2 2013 | Q3 2023 | 30 |
| BSX | BOSTON SCIENTIFIC CORP | 22 | 1 | 0.00% | 1.11% | 3.53% | Q2 2013 | Q3 2023 | 29 |
| AMGN | AMGEN INC | 16 | 12 | 0.23% | 2.58% | 7.13% | Q2 2013 | Q3 2023 | 28 |
| UNH | UNITEDHEALTH GRP INC | 16 | 4 | 0.63% | 1.68% | 3.72% | Q3 2015 | Q3 2023 | 27 |
| ABT | ABBOTT LABS | 24 | 3 | 0.62% | 1.02% | 2.73% | Q4 2014 | Q3 2023 | 27 |
| TDOC | TELADOC INC | 26 | 26 | 0.31% | 2.59% | 6.14% | Q3 2015 | Q4 2021 | 26 |
| PTLA | PORTOLA PHARMACEUTICALS | 16 | 10 | 0.82% | 2.21% | 3.53% | Q2 2013 | Q4 2019 | 26 |
| EVH | EVOLENT HEALTH INC | 26 | 26 | 0.66% | 1.99% | 3.18% | Q2 2017 | Q3 2023 | 26 |
| DXCM | DEXCOM INC | 17 | 1 | 0.12% | 1.32% | 3.54% | Q2 2013 | Q3 2023 | 26 |
| ALNY | ALNYLAM PHARMACUETICAL... | 12 | 4 | 0.06% | 1.44% | 4.91% | Q2 2016 | Q3 2023 | 25 |
| CELG | CELGENE CORP | 24 | 24 | 0.21% | 4.27% | 7.25% | Q2 2013 | Q1 2019 | 24 |
| XLRN | ACCELERON PHARMA | 22 | 1 | 0.02% | 1.39% | 3.78% | Q4 2013 | Q2 2020 | 24 |
| ILMN | ILLUMINA INC | 16 | 3 | 0.09% | 0.52% | 2.96% | Q2 2013 | Q3 2023 | 24 |
| ALXN | ALEXION PHARM INC | 13 | 3 | 0.41% | 2.50% | 6.17% | Q2 2013 | Q1 2021 | 23 |
| NVS | NOVARTIS AG | 12 | 11 | 0.02% | 1.62% | 5.10% | Q2 2013 | Q3 2019 | 23 |
| JNJ | JOHNSON & JOHNSON | 13 | 9 | 0.30% | 2.11% | 5.12% | Q1 2017 | Q3 2023 | 22 |
| IRTC | IRHYTHM TECHNOLOGIES INC | 15 | 7 | 0.52% | 1.34% | 2.54% | Q2 2017 | Q3 2023 | 22 |
| INSM | INSMED INC | 11 | 1 | 0.04% | 1.27% | 2.20% | Q3 2013 | Q3 2023 | 22 |
| ALGN | ALIGN TECHNOLOGY INC | 14 | 8 | 0.19% | 1.13% | 2.61% | Q2 2013 | Q1 2022 | 22 |
| SRPT | SAREPTA THERAPEUTICS INC | 8 | 6 | 0.04% | 1.03% | 3.04% | Q4 2016 | Q3 2023 | 22 |
| MNTA | MOMENTA PHARMACEUTICAL... | 20 | 1 | 0.04% | 0.53% | 1.02% | Q2 2013 | Q2 2020 | 22 |
| ZLAB | ZAI LAB LTD | 14 | 8 | 0.01% | 0.11% | 0.92% | Q3 2017 | Q3 2023 | 22 |
| ATRC | ATRICURE INC | 21 | 21 | 0.93% | 1.93% | 2.59% | Q3 2018 | Q3 2023 | 21 |
| BMY | BRISTOL-MYERS SQUIBB CO | 15 | 6 | 0.36% | 1.09% | 2.46% | Q1 2018 | Q2 2023 | 21 |
| ABBV | ABBVIE INC | 15 | 1 | 0.58% | 1.02% | 1.74% | Q4 2013 | Q3 2023 | 20 |
| APLS | APELLIS PHARMACEUTICAL... | 11 | 1 | 0.04% | 2.62% | 4.75% | Q4 2017 | Q3 2023 | 19 |
| HALO | HALOZYME THERAPEUTICS INC | 11 | 1 | 0.05% | 1.58% | 3.28% | Q2 2013 | Q3 2023 | 19 |
| COLL | COLLEGIUM PHARMACEUTICAL | 18 | 18 | 0.26% | 2.09% | 3.63% | Q1 2016 | Q2 2020 | 18 |
| SHPG | SHIRE PLC | 16 | 2 | 0.02% | 2.02% | 3.53% | Q2 2013 | Q3 2018 | 18 |
| GBT | GLOBAL BLOOD THERAPEUT... | 18 | 18 | 0.96% | 1.62% | 2.33% | Q2 2016 | Q3 2020 | 18 |
| NBIX | NEUROCRINE BIOSCIENCES | 10 | 1 | 0.05% | 1.47% | 4.75% | Q4 2015 | Q3 2023 | 18 |
| NXTM | NXSTAGE MEDICAL | 18 | 18 | 0.26% | 1.13% | 4.09% | Q2 2013 | Q3 2017 | 18 |
| MOH | MOLINA HEALTHCARE INC | 6 | 3 | 0.25% | 0.82% | 1.96% | Q1 2016 | Q3 2022 | 18 |
| TEVA | TEVA PHARMACEUTICAL | 14 | 1 | 0.02% | 2.11% | 3.93% | Q2 2013 | Q3 2018 | 17 |
| SGEN | SEATTLE GENETICS INC | 11 | 2 | 0.11% | 1.24% | 2.55% | Q2 2013 | Q3 2020 | 17 |
| EW | EDWARDS LIFESCIENCES CORP | 6 | 1 | 0.21% | 1.21% | 3.50% | Q2 2013 | Q3 2023 | 17 |
| UTHR | UNITED THERAPEUTICS | 9 | 1 | 0.07% | 0.61% | 1.30% | Q2 2013 | Q3 2023 | 17 |
| ARAY | ACCURAY INC | 9 | 3 | 0.00% | 0.43% | 1.57% | Q2 2013 | Q1 2018 | 17 |
| AERI | AERIE PHARMACEUTICALS | 16 | 16 | 0.16% | 2.86% | 5.56% | Q2 2016 | Q1 2020 | 16 |
| TNDM | TANDEM DIABETES CARE INC | 16 | 16 | 0.14% | 1.60% | 4.40% | Q3 2018 | Q2 2022 | 16 |
| IMGN | IMMUNOGEN INC | 7 | 3 | 0.02% | 1.25% | 3.15% | Q2 2013 | Q3 2023 | 16 |
| ISRG | INTUITIVE SURGIC INC | 15 | 1 | 0.04% | 1.11% | 2.98% | Q4 2013 | Q3 2018 | 16 |
| ALDR | ALDER BIOPHARMACEUTICALS | 12 | 4 | 0.03% | 1.10% | 1.84% | Q2 2014 | Q4 2018 | 16 |
| BPMC | BLUEPRINT MEDICINES CORP | 8 | 1 | 0.03% | 0.98% | 2.35% | Q3 2018 | Q3 2023 | 16 |
| NVO | NOVO-NORDISK AS | 16 | 16 | 0.08% | 0.57% | 1.82% | Q2 2013 | Q1 2017 | 16 |
| ASND | ASCENDIS PHARMA A/S | 11 | 5 | 0.02% | 0.11% | 0.51% | Q1 2015 | Q3 2023 | 16 |
| ACAD | ACADIA PHARMACEUTICALS... | 9 | 1 | 0.10% | 2.06% | 4.26% | Q1 2016 | Q3 2023 | 15 |
| ABMD | ABIOMED INC | 14 | 1 | 0.05% | 2.00% | 3.83% | Q1 2016 | Q2 2020 | 15 |
| RCM | R1 RCM INC | 15 | 15 | 0.79% | 1.81% | 2.51% | Q3 2018 | Q1 2022 | 15 |
| INSP | INSPIRE MED SYS INC | 10 | 5 | 0.59% | 1.45% | 2.77% | Q1 2019 | Q2 2023 | 15 |
| WMGI | WRIGHT MED GROUP N V | 15 | 15 | 0.15% | 1.40% | 3.79% | Q1 2016 | Q3 2019 | 15 |
| PODD | INSULET CORP | 7 | 2 | 0.52% | 0.86% | 1.14% | Q4 2017 | Q3 2023 | 15 |
| CI | CIGNA CORP NEW | 12 | 3 | 0.19% | 0.78% | 1.73% | Q4 2018 | Q3 2022 | 15 |
| MRNA | MODERNA INC | 15 | 15 | 0.13% | 0.49% | 0.93% | Q1 2020 | Q3 2023 | 15 |
| SAGE | SAGE THERAPEUTICS | 9 | 1 | 0.03% | 0.35% | 0.65% | Q1 2016 | Q2 2020 | 15 |
| BGNE | BEIGENE LTD | 11 | 4 | 0.12% | 0.18% | 0.28% | Q3 2018 | Q3 2023 | 15 |
| ARVN | ARVINAS INC | 14 | 14 | 0.03% | 1.69% | 3.18% | Q2 2020 | Q3 2023 | 14 |
| RCUS | ARCUS BIOSCIENCES INC | 13 | 1 | 0.70% | 1.43% | 2.14% | Q1 2020 | Q3 2023 | 14 |
| CLVS | CLOVIS ONCOLOGY | 6 | 3 | 0.33% | 1.23% | 2.67% | Q2 2013 | Q3 2018 | 14 |
| CI | CIGNA CORP | 6 | 2 | 0.28% | 1.02% | 3.14% | Q2 2014 | Q3 2018 | 14 |
| RCKT | ROCKET PHARMACEUTICALS... | 12 | 2 | 0.44% | 0.96% | 1.68% | Q1 2018 | Q3 2023 | 14 |
| MRTX | MIRATI THERAPEUTICS INC | 12 | 2 | 0.03% | 0.92% | 1.67% | Q1 2020 | Q3 2023 | 14 |
| DHR | DANAHER CORPORATION | 13 | 1 | 0.04% | 0.43% | 0.83% | Q3 2018 | Q3 2023 | 14 |
| SWAV | SHOCKWAVE MED INC | 10 | 3 | 0.43% | 1.84% | 5.80% | Q1 2019 | Q3 2023 | 13 |
| EXEL | EXELIXIS INC | 12 | 1 | 0.05% | 1.43% | 2.55% | Q1 2020 | Q3 2023 | 13 |
| SILK | SILK ROAD MEDICAL INC | 8 | 5 | 0.44% | 1.38% | 2.24% | Q4 2019 | Q2 2023 | 13 |
| SGNT | SAGENT PHARMACEUTICALS | 13 | 13 | 0.38% | 0.85% | 1.56% | Q2 2013 | Q2 2016 | 13 |
| TGTX | TG THERAPEUTICS INC | 5 | 3 | 0.09% | 0.73% | 1.88% | Q1 2015 | Q4 2021 | 13 |
| HZNP | HORIZON THERAPEUTICS P... | 12 | 1 | 0.05% | 0.63% | 1.56% | Q2 2020 | Q3 2023 | 13 |
| HUM | HUMANA INC | 8 | 2 | 0.03% | 0.44% | 1.34% | Q3 2018 | Q3 2023 | 13 |
| AGIO | AGIOS PHARMACEUTICS | 7 | 1 | 0.05% | 0.34% | 0.70% | Q2 2016 | Q2 2020 | 13 |
| ICPT | INTERCEPT PHARMACEUTICALS | 12 | 12 | 0.74% | 1.23% | 1.79% | Q1 2014 | Q4 2016 | 12 |
| EXAS | EXACT SCIENCES CORP | 8 | 1 | 0.18% | 1.15% | 3.20% | Q3 2017 | Q3 2021 | 12 |
| ICLR | ICON PLC | 10 | 1 | 0.03% | 1.10% | 2.13% | Q3 2018 | Q3 2023 | 12 |
| PRTA | PROTHENA CORP PLC | 8 | 4 | 0.63% | 1.08% | 1.73% | Q1 2016 | Q3 2023 | 12 |
| DNLI | DENALI THERAPEUTICS INC | 11 | 1 | 0.02% | 0.89% | 1.47% | Q2 2020 | Q3 2023 | 12 |
| CNC | CENTENE CORP DEL | 6 | 3 | 0.03% | 0.84% | 2.34% | Q3 2018 | Q3 2022 | 12 |
| SGEN | SEAGEN INC | 12 | 12 | 0.26% | 0.80% | 1.38% | Q4 2020 | Q3 2023 | 12 |
| ALKS | ALKERMES PLC | 6 | 1 | 0.04% | 0.63% | 1.33% | Q1 2015 | Q3 2023 | 12 |
| AKRXQ | AKORN INC | 12 | 12 | 0.04% | 0.54% | 1.07% | Q2 2013 | Q1 2016 | 12 |
| GH | GUARDANT HEALTH INC | 12 | 12 | 0.02% | 0.39% | 0.83% | Q1 2020 | Q4 2022 | 12 |
| ARGX | ARGENX SE | 6 | 6 | 0.04% | 0.07% | 0.12% | Q2 2020 | Q3 2023 | 12 |
| LJPC | LA JOLLA PHARMACLS | 11 | 11 | 0.27% | 2.46% | 4.28% | Q1 2017 | Q3 2019 | 11 |
| HRC | HILL-ROM HLDS INC | 11 | 11 | 0.73% | 1.65% | 2.52% | Q4 2017 | Q2 2020 | 11 |
| THC | TENET HEALTHCARE CORP | 10 | 1 | 0.03% | 1.05% | 2.18% | Q2 2020 | Q3 2023 | 11 |
| MNKKQ | MALLINCKRODT PLC | 11 | 11 | 0.08% | 0.97% | 2.28% | Q3 2013 | Q1 2016 | 11 |
| ARQT | ARCUTIS BIOTHERAPEUTIC... | 11 | 11 | 0.01% | 0.86% | 1.93% | Q1 2021 | Q3 2023 | 11 |
| ZBH | ZIMMER BIOMET HOLDINGS... | 6 | 1 | 0.00% | 0.84% | 1.58% | Q2 2015 | Q3 2021 | 11 |
| QURE | UNIQURE N.V. | 5 | 1 | 0.06% | 0.65% | 1.49% | Q4 2014 | Q2 2020 | 11 |
| OBSV | OBSEVA SA | 11 | 11 | 0.09% | 0.63% | 1.08% | Q1 2017 | Q3 2019 | 11 |
| IART | INTEGRA LIFESCIENCE | 9 | 1 | 0.00% | 0.62% | 1.45% | Q2 2015 | Q2 2020 | 11 |
| ALBO | ALBIREO PHARMA INC | 11 | 11 | 0.06% | 0.62% | 0.94% | Q1 2017 | Q3 2019 | 11 |
| NTLA | INTELLIA THERAPEUTICS INC | 9 | 2 | 0.02% | 0.61% | 1.27% | Q2 2016 | Q3 2023 | 11 |
| HTWR | HEARTWARE INTL INC | 11 | 11 | 0.38% | 0.60% | 1.70% | Q2 2013 | Q4 2015 | 11 |
| MTEM | MOLECULAR TEMPLATES INC | 11 | 11 | 0.15% | 0.44% | 0.93% | Q3 2018 | Q1 2021 | 11 |
| SYK | STRYKER CORPORATION | 6 | 1 | 0.00% | 0.23% | 0.44% | Q2 2015 | Q4 2022 | 11 |
| CRSP | CRISPR THERAPEUTICS AG | 9 | 2 | 0.02% | 0.13% | 0.77% | Q1 2020 | Q4 2022 | 11 |
| JAZZ | JAZZ PHARMA PLC | 6 | 1 | 0.05% | 0.07% | 0.10% | Q1 2015 | Q3 2023 | 11 |
| LEGN | LEGEND BIOTECH CORP | 11 | 11 | 0.02% | 0.07% | 0.11% | Q1 2021 | Q3 2023 | 11 |
| ACHC | ACADIA HEALTHCARE | 10 | 10 | 0.39% | 2.00% | 3.52% | Q3 2015 | Q4 2017 | 10 |
| TPTX | TURNING POINT THERAPEU... | 10 | 10 | 0.76% | 1.50% | 2.21% | Q1 2020 | Q2 2022 | 10 |
| MYL | MYLAN N V | 6 | 1 | 0.06% | 1.41% | 2.78% | Q1 2015 | Q2 2020 | 10 |
| PRGO | PERRIGO CO | 8 | 1 | 0.10% | 1.09% | 2.32% | Q4 2013 | Q2 2020 | 10 |
| BLU | BELLUS HEALTH INC NEW | 10 | 10 | 0.32% | 0.82% | 1.28% | Q4 2020 | Q1 2023 | 10 |
| HOLX | HOLOGIC INC | 6 | 1 | 0.00% | 0.60% | 1.52% | Q2 2013 | Q3 2021 | 10 |
| AZN | ASTRAZENECA | 6 | 1 | 0.03% | 0.49% | 1.42% | Q3 2018 | Q3 2023 | 10 |
| CYTK | CYTOKINETICS INC | 7 | 3 | 0.01% | 0.46% | 0.80% | Q3 2018 | Q3 2023 | 10 |
| NKTR | NEKTAR THERAPEUTICS | 5 | 1 | 0.01% | 0.33% | 1.15% | Q1 2015 | Q2 2020 | 10 |
| SBPH | SPRING BK PHARMACEUTICALS | 10 | 10 | 0.12% | 0.24% | 0.37% | Q2 2017 | Q3 2019 | 10 |
| SRRA | SIERRA ONCOLOGY INC | 10 | 10 | 0.00% | 0.04% | 0.09% | Q1 2017 | Q2 2019 | 10 |
| NARI | INARI MED INC | 9 | 9 | 1.48% | 2.13% | 2.61% | Q3 2021 | Q3 2023 | 9 |
| IMMU | IMMUNOMEDICS INC | 6 | 3 | 0.70% | 2.12% | 4.39% | Q2 2018 | Q3 2020 | 9 |
| AGLY | AGILITI INC | 9 | 9 | 1.29% | 1.58% | 1.83% | Q2 2021 | Q2 2023 | 9 |
| NUVA | NUVASIVE INC | 7 | 1 | 0.02% | 1.56% | 3.72% | Q1 2016 | Q2 2020 | 9 |
| OMED | ONCOMED PHARMACEUTICALS | 9 | 9 | 0.08% | 1.26% | 1.86% | Q3 2013 | Q3 2015 | 9 |
| AXNX | AXONICS INC | 7 | 2 | 0.30% | 1.21% | 1.89% | Q2 2021 | Q3 2023 | 9 |
| NVAX | NOVAVAX INC | 9 | 9 | 0.01% | 1.19% | 2.63% | Q3 2020 | Q3 2022 | 9 |
| RARX | RA PHARMACEUTICALS | 5 | 4 | 0.37% | 1.18% | 2.39% | Q4 2016 | Q3 2019 | 9 |
| EFFECTOR THERAPEUTICS INC | 9 | 9 | 0.16% | 1.11% | 3.37% | Q3 2021 | Q3 2023 | 9 | |
| TMCI | TREACE MED CONCEPTS INC | 9 | 9 | 0.61% | 1.06% | 1.77% | Q2 2021 | Q2 2023 | 9 |
| PRAH | PRA HEALTH SCIENCES INC | 6 | 1 | 0.20% | 1.06% | 1.55% | Q1 2016 | Q1 2021 | 9 |
| IRWD | IRONWOOD PHARMACEUTICA... | 5 | 1 | 0.01% | 1.05% | 2.73% | Q2 2013 | Q2 2020 | 9 |
| HMSY | HMS HOLDINGS CORP | 9 | 9 | 0.04% | 0.98% | 1.67% | Q3 2018 | Q3 2020 | 9 |
| FATE | FATE THERAPEUTICS INC | 9 | 9 | 0.36% | 0.96% | 1.70% | Q4 2020 | Q4 2022 | 9 |
| MDGL | MADRIGAL PHARMACEUTICALS | 6 | 3 | 0.02% | 0.59% | 1.19% | Q4 2017 | Q3 2023 | 9 |
| RALLYBIO CORP | 9 | 9 | 0.25% | 0.54% | 0.79% | Q3 2021 | Q3 2023 | 9 | |
| ADXS | ADVAXIS INC | 7 | 2 | 0.08% | 0.52% | 0.95% | Q4 2014 | Q1 2017 | 9 |
| ITOS | ITEOS THERAPEUTICS INC | 5 | 4 | 0.02% | 0.47% | 1.34% | Q2 2021 | Q3 2023 | 9 |
| BNTX | BIONTECH SE | 9 | 9 | 0.02% | 0.07% | 0.12% | Q3 2021 | Q3 2023 | 9 |
| FUSN | FUSION PHARMACEUTICALS... | 9 | 9 | 0.02% | 0.03% | 0.05% | Q3 2021 | Q3 2023 | 9 |
| HQY | HEALTHEQUITY INC | 7 | 1 | 0.06% | 2.24% | 3.08% | Q2 2020 | Q3 2023 | 8 |
| KTWO | K2M GROUP HOLDINGS | 8 | 8 | 0.34% | 2.22% | 2.74% | Q4 2016 | Q3 2018 | 8 |
| TFX | TELEFLEX INCORPORATED | 8 | 8 | 0.73% | 1.91% | 2.58% | Q4 2019 | Q3 2021 | 8 |
| ARNA | ARENA PHARMACEUTICALS INC | 7 | 1 | 0.04% | 1.88% | 3.22% | Q3 2018 | Q4 2021 | 8 |
| PRVA | PRIVIA HEALTH GROUP INC | 8 | 8 | 1.41% | 1.77% | 2.22% | Q4 2021 | Q3 2023 | 8 |
| SYNH | SYNEOS HEALTH INC | 6 | 1 | 0.03% | 1.66% | 2.54% | Q3 2018 | Q3 2022 | 8 |
| ASMB | ASSEMBLY BIOSCIENCES INC | 8 | 8 | 0.48% | 1.41% | 2.12% | Q4 2018 | Q3 2020 | 8 |
| VCRA | VOCERA COMMUNICATIONS | 8 | 8 | 0.28% | 1.22% | 2.04% | Q2 2018 | Q1 2020 | 8 |
| FGEN | FIBROGEN INC | 8 | 8 | 0.05% | 1.20% | 2.35% | Q1 2019 | Q4 2020 | 8 |
| AGN | ALLERGAN PLC | 4 | 1 | 0.14% | 0.95% | 2.04% | Q2 2015 | Q3 2019 | 8 |
| VRAY | VIEWRAY INC | 8 | 8 | 0.62% | 0.93% | 1.13% | Q4 2017 | Q3 2019 | 8 |
| UMRX | UNUM THERAPEUTICS | 8 | 8 | 0.02% | 0.83% | 1.74% | Q1 2018 | Q4 2019 | 8 |
| ARWR | ARROWHEAD PHARMACEUTIC... | 5 | 1 | 0.06% | 0.75% | 1.05% | Q2 2020 | Q3 2023 | 8 |
| NVTA | INVITAE CORP | 4 | 1 | 0.05% | 0.75% | 1.66% | Q1 2015 | Q4 2021 | 8 |
| OLMA | OLEMA PHARMACEUTICALS INC | 5 | 3 | 0.03% | 0.72% | 1.11% | Q1 2021 | Q3 2023 | 8 |
| STAA | STAAR SURGICAL CO | 7 | 1 | 0.37% | 0.67% | 0.89% | Q2 2021 | Q3 2023 | 8 |
| MASI | MASIMO CORP | 7 | 1 | 0.46% | 0.66% | 0.81% | Q1 2017 | Q2 2020 | 8 |
| INTEC PHARMA LTD JERUS... | 8 | 8 | 0.23% | 0.55% | 1.13% | Q3 2017 | Q2 2019 | 8 | |
| SVRA | SAVARA INC | 8 | 8 | 0.21% | 0.52% | 0.96% | Q4 2017 | Q3 2019 | 8 |
| MGTX | MEIRAGTX HOLDINGS PLC | 8 | 8 | 0.17% | 0.50% | 0.73% | Q2 2018 | Q1 2020 | 8 |
| IMDZ | IMMUNE DESIGN CORP | 7 | 1 | 0.03% | 0.35% | 0.73% | Q3 2014 | Q2 2017 | 8 |
| CTLT | CATALENT INC | 4 | 1 | 0.02% | 0.31% | 0.87% | Q1 2015 | Q3 2021 | 8 |
| GBIO | GENERATION BIO CO | 4 | 2 | 0.04% | 0.28% | 0.99% | Q2 2020 | Q3 2023 | 8 |
| MEIP | MEI PHARMA INC | 4 | 4 | 0.01% | 0.15% | 0.57% | Q3 2018 | Q4 2021 | 8 |
| TNDM | TANDEM DIABETES CARE | 7 | 1 | 0.00% | 0.05% | 0.11% | Q4 2013 | Q1 2016 | 8 |
| MYL | MYLAN INC | 7 | 7 | 2.18% | 3.30% | 4.34% | Q2 2013 | Q4 2014 | 7 |
| P103PS | NPS PHARMACEUTICALS | 7 | 7 | 1.03% | 2.14% | 3.19% | Q2 2013 | Q4 2014 | 7 |
| AGN | ALLERGAN INC | 7 | 7 | 1.38% | 2.10% | 2.69% | Q2 2013 | Q4 2014 | 7 |
| AVIR | ATEA PHARMACEUTICALS INC | 4 | 3 | 0.24% | 1.82% | 6.27% | Q4 2020 | Q3 2023 | 7 |
| MDVN | MEDIVATION INC | 4 | 3 | 0.03% | 1.71% | 3.95% | Q2 2013 | Q1 2015 | 7 |
| GEVA | SYNAGEVA BIOPHARMA | 7 | 7 | 1.35% | 1.71% | 2.29% | Q3 2013 | Q1 2015 | 7 |
| ITCI | INTRA CELLULAR THERA | 6 | 1 | 0.02% | 1.02% | 1.26% | Q2 2020 | Q3 2023 | 7 |
| ZNTL | ZENTALIS PHARMACEUTICA... | 5 | 2 | 0.26% | 0.95% | 1.56% | Q2 2020 | Q3 2023 | 7 |
| RLYP | RELYPSA INC | 6 | 1 | 0.05% | 0.80% | 1.16% | Q4 2013 | Q3 2015 | 7 |
| A | AGILENT TECHNOLOGIES INC | 7 | 7 | 0.03% | 0.68% | 1.75% | Q1 2021 | Q3 2022 | 7 |
| EVLO | EVELO BIOSCIENCES | 7 | 7 | 0.38% | 0.62% | 0.77% | Q2 2018 | Q4 2019 | 7 |
| IQV | IQVIA HOLDINGS INC | 6 | 1 | 0.06% | 0.61% | 0.83% | Q2 2021 | Q3 2023 | 7 |
| KPTI | KARYOPHARM THERAPEUTIC... | 6 | 1 | 0.04% | 0.59% | 0.89% | Q4 2013 | Q3 2015 | 7 |
| TTPH | TETRAPHASE PHARMACEUTI... | 4 | 3 | 0.00% | 0.41% | 1.77% | Q1 2015 | Q2 2019 | 7 |
| CMPI | CHECKMATE PHARMACEUTIC... | 7 | 7 | 0.18% | 0.38% | 0.59% | Q3 2020 | Q1 2022 | 7 |
| VRX | VALEANT PHARMA INTL | 7 | 7 | 0.01% | 0.36% | 0.90% | Q1 2014 | Q3 2015 | 7 |
| TRNX | TORNIER N V | 6 | 1 | 0.00% | 0.35% | 0.47% | Q2 2013 | Q2 2015 | 7 |
| ENDP | ENDO INTL PLC | 4 | 1 | 0.01% | 0.32% | 1.00% | Q1 2015 | Q2 2020 | 7 |
| ANTM | ELEVANCE HEALTH INC | 4 | 3 | 0.10% | 0.32% | 0.60% | Q3 2018 | Q3 2022 | 7 |
| FIXX | HOMOLOGY MEDICINES | 4 | 3 | 0.05% | 0.24% | 0.46% | Q1 2018 | Q2 2020 | 7 |
| XENT | INTERSECT ENT INC | 5 | 1 | 0.00% | 0.24% | 0.72% | Q2 2015 | Q3 2018 | 7 |
| UHS | UNIVERSAL HEALTH SVC | 3 | 1 | 0.04% | 0.18% | 0.40% | Q4 2014 | Q2 2020 | 7 |
| AMPH | AMPHASTAR PHARMACTLS | 7 | 7 | 0.02% | 0.17% | 0.42% | Q3 2014 | Q1 2016 | 7 |
| MEDP | MEDPACE HOLDINGS | 6 | 1 | 0.03% | 0.04% | 0.06% | Q2 2020 | Q3 2023 | 7 |
| ARRY | ARRAY BIOPHARMA INC | 6 | 6 | 1.85% | 3.24% | 4.40% | Q1 2018 | Q2 2019 | 6 |
| B108PS | ACTAVIS PLC | 6 | 6 | 2.22% | 3.11% | 4.23% | Q4 2013 | Q1 2015 | 6 |
| THRX | THERAVANCE INC | 6 | 6 | 0.70% | 2.62% | 3.82% | Q2 2013 | Q3 2014 | 6 |
| R1 RCM INC | 6 | 6 | 2.18% | 2.55% | 2.87% | Q2 2022 | Q3 2023 | 6 | |
| KERX | KERYX BIOPHARMACEUTICA... | 6 | 6 | 1.54% | 2.08% | 2.48% | Q4 2013 | Q1 2015 | 6 |
| LH | LABORATORY CORP AMER H... | 6 | 6 | 0.23% | 1.54% | 2.90% | Q2 2020 | Q3 2021 | 6 |
| LNTH | LANTHEUS HLDGS INC | 6 | 6 | 0.96% | 1.38% | 1.87% | Q2 2022 | Q3 2023 | 6 |
| RGEN | REPLIGEN CORP | 6 | 6 | 0.65% | 1.35% | 1.84% | Q2 2020 | Q3 2021 | 6 |
| ALHC | ALIGNMENT HEALTHCARE INC | 4 | 2 | 0.53% | 1.21% | 1.75% | Q1 2021 | Q1 2023 | 6 |
| RMD | RESMED INC | 6 | 6 | 0.99% | 1.18% | 1.32% | Q2 2020 | Q3 2021 | 6 |
| BBIO | BRIDGEBIO PHARMA INC | 5 | 1 | 0.03% | 1.00% | 1.84% | Q4 2020 | Q3 2023 | 6 |
| CHNG | CHANGE HEALTHCARE INC | 6 | 6 | 0.10% | 0.89% | 1.47% | Q2 2019 | Q3 2020 | 6 |
| F113PS | COVIDIEN PLC | 6 | 6 | 0.64% | 0.88% | 1.06% | Q2 2013 | Q3 2014 | 6 |
| STML | STEMLINE THERAPEUTICS | 6 | 6 | 0.03% | 0.84% | 1.62% | Q3 2018 | Q4 2019 | 6 |
| KRTX | KARUNA THERAPEUTICS | 6 | 6 | 0.61% | 0.84% | 0.94% | Q2 2022 | Q3 2023 | 6 |
| NEURODERM LTD | 6 | 6 | 0.18% | 0.83% | 1.52% | Q2 2016 | Q3 2017 | 6 | |
| NTRA | NATERA INC | 5 | 1 | 0.05% | 0.55% | 0.99% | Q2 2020 | Q4 2021 | 6 |
| DBVT | DBV TECHNOLOGIES | 6 | 6 | 0.14% | 0.34% | 0.70% | Q3 2016 | Q4 2017 | 6 |
| HCA | HCA HLDGS INC | 3 | 3 | 0.08% | 0.31% | 0.67% | Q4 2014 | Q1 2019 | 6 |
| ALVR | ALLOVIR INC | 6 | 6 | 0.03% | 0.31% | 0.66% | Q3 2020 | Q4 2021 | 6 |
| RGNX | REGENXBIO INC | 5 | 1 | 0.03% | 0.30% | 0.50% | Q3 2015 | Q3 2018 | 6 |
| AVXS | AVEXIS INC | 5 | 1 | 0.10% | 0.27% | 0.59% | Q1 2016 | Q1 2018 | 6 |
| IONS | IONIS PHARMACEUTICAL | 3 | 1 | 0.03% | 0.24% | 0.85% | Q4 2015 | Q4 2022 | 6 |
| NVCR | NOVOCURE LTD | 4 | 1 | 0.02% | 0.15% | 0.75% | Q2 2020 | Q1 2023 | 6 |
| LCI | LANNETT CO INC | 3 | 3 | 0.06% | 0.13% | 0.25% | Q1 2015 | Q3 2016 | 6 |
| SNY | SANOFI | 6 | 6 | 0.07% | 0.10% | 0.13% | Q2 2022 | Q3 2023 | 6 |
| RPRX | ROYALTY PHARMA PLC | 6 | 6 | 0.08% | 0.09% | 0.12% | Q2 2022 | Q3 2023 | 6 |
| WX | WUXI PHARMATECH ADS | 6 | 6 | 0.01% | 0.03% | 0.06% | Q4 2013 | Q1 2015 | 6 |
| CHRS | COHERUS BIOSCIENCES | 4 | 2 | 0.02% | 0.02% | 0.05% | Q1 2015 | Q4 2018 | 6 |
| APRE | APREA THERAPEUTICS INC | 5 | 5 | 0.06% | 5.02% | 10.07% | Q4 2019 | Q4 2020 | 5 |
| OCDX | ORTHO CLINICAL DIAGNOS... | 5 | 5 | 1.72% | 2.30% | 2.80% | Q1 2021 | Q1 2022 | 5 |
| PPD | PPD INC | 5 | 5 | 1.53% | 2.26% | 3.06% | Q1 2020 | Q1 2021 | 5 |
| DCPH | DECIPHERA PHARMACEUTIC... | 4 | 1 | 0.40% | 1.41% | 1.97% | Q1 2020 | Q3 2021 | 5 |
| LOXO | LOXO ONCOLOGY INC | 4 | 1 | 0.06% | 1.39% | 2.91% | Q1 2017 | Q3 2018 | 5 |
| TSRO | TESARO INC | 3 | 2 | 0.38% | 1.33% | 2.49% | Q4 2015 | Q1 2018 | 5 |
| ADMS | ADAMAS PHARMACEUTICALS | 5 | 5 | 0.69% | 1.28% | 1.92% | Q1 2018 | Q1 2019 | 5 |
| TVTX | TRAVERE THERAPEUTICS | 5 | 5 | 1.12% | 1.24% | 1.55% | Q2 2022 | Q2 2023 | 5 |
| TRHC | TABULA RASA HEALTHCARE... | 5 | 5 | 0.12% | 1.22% | 1.77% | Q3 2019 | Q3 2020 | 5 |
| RETA | REATA PHARMACEUTIC | 3 | 2 | 0.05% | 1.16% | 2.46% | Q4 2019 | Q2 2023 | 5 |
| SBTX | SILVERBACK THERAPEUT | 5 | 5 | 0.77% | 1.11% | 1.40% | Q3 2022 | Q3 2023 | 5 |
| REPL | REPLIMUNE GROUP INC | 4 | 1 | 0.89% | 1.11% | 1.80% | Q4 2020 | Q3 2023 | 5 |
| AMYLYX PHARMACEUTIC | 5 | 5 | 0.26% | 1.06% | 1.39% | Q3 2022 | Q3 2023 | 5 | |
| CERT | CERTARA INC | 4 | 1 | 0.45% | 1.02% | 1.50% | Q4 2020 | Q3 2022 | 5 |
| CNVY | CONVEY HLDG PARENT INC | 5 | 5 | 0.54% | 0.97% | 1.61% | Q2 2021 | Q2 2022 | 5 |
| CSII | CARDIOVASCULAR SYS | 3 | 1 | 0.00% | 0.97% | 1.88% | Q2 2015 | Q2 2020 | 5 |
| CMRX | CHIMERIX INC | 3 | 2 | 0.21% | 0.70% | 0.98% | Q2 2014 | Q4 2015 | 5 |
| RPTX | REPARE THERAPEUTICS INC | 5 | 5 | 0.02% | 0.69% | 1.13% | Q1 2021 | Q1 2022 | 5 |
| AVTE | AEROVATE THERAPEUTICS INC | 5 | 5 | 0.50% | 0.67% | 0.92% | Q2 2021 | Q2 2022 | 5 |
| TALS | TALARIS THERAPEUTICS INC | 5 | 5 | 0.21% | 0.59% | 0.92% | Q2 2021 | Q2 2022 | 5 |
| ACHN | ACHILLION PHARMACEUTICALS | 3 | 2 | 0.04% | 0.59% | 1.30% | Q2 2013 | Q2 2015 | 5 |
| OM | OUTSET MED INC | 3 | 1 | 0.16% | 0.54% | 0.90% | Q3 2020 | Q1 2023 | 5 |
| ESPR | ESPERION THERAPEUTICS | 4 | 1 | 0.02% | 0.53% | 1.05% | Q4 2017 | Q2 2020 | 5 |
| EXSCIENTIA PLC | 3 | 2 | 0.21% | 0.49% | 0.90% | Q4 2021 | Q1 2023 | 5 | |
| CTSO | CYTOSORBENTS CORP | 5 | 5 | 0.15% | 0.45% | 1.12% | Q3 2020 | Q3 2021 | 5 |
| DNAI | PRONAI THERAPEUTICS | 5 | 5 | 0.04% | 0.39% | 0.79% | Q3 2015 | Q3 2016 | 5 |
| RARE | ULTRAGENYX PHARMACEUTI... | 2 | 1 | 0.05% | 0.24% | 0.97% | Q3 2018 | Q2 2022 | 5 |
| ENTL | ENTELLUS MED INC | 4 | 1 | 0.00% | 0.19% | 0.29% | Q2 2015 | Q4 2016 | 5 |
| CMTA | CLEMENTIA PHARMACEUTICALS | 5 | 5 | 0.07% | 0.15% | 0.19% | Q3 2017 | Q3 2018 | 5 |
| MCK | MCKESSON CORP | 4 | 1 | 0.05% | 0.07% | 0.09% | Q1 2015 | Q3 2018 | 5 |
| BDX | BECTON DICKINSON | 4 | 1 | 0.00% | 0.07% | 0.09% | Q2 2015 | Q2 2019 | 5 |
| PRFMF | PROFOUND MEDICAL | 3 | 2 | 0.02% | 0.04% | 0.06% | Q4 2015 | Q1 2017 | 5 |
| CRVS | CORVUS PHARMACEUTICALS | 4 | 1 | 0.01% | 0.04% | 0.16% | Q1 2017 | Q2 2019 | 5 |
| ALGS | ALIGOS THERAPEUTICS INC | 5 | 5 | 0.02% | 0.03% | 0.04% | Q4 2020 | Q4 2021 | 5 |
| CCXI | CHEMOCENTRYX INC | 4 | 1 | 0.02% | 0.03% | 0.04% | Q3 2018 | Q2 2020 | 5 |
| OPCH | OPTION CARE HEALTH | 4 | 4 | 1.59% | 1.97% | 2.36% | Q4 2022 | Q3 2023 | 4 |
| RXDX | PROMETHEUS BIOSCIENC | 4 | 4 | 0.98% | 1.70% | 2.39% | Q2 2022 | Q1 2023 | 4 |
| RDNT | RADNET INC | 4 | 4 | 1.08% | 1.70% | 2.17% | Q4 2022 | Q3 2023 | 4 |
| HCAT | HEALTH CATALYST INC | 3 | 1 | 1.17% | 1.49% | 1.83% | Q2 2020 | Q1 2022 | 4 |
| CLDX | CELLDEX THERAPEUTICS | 3 | 1 | 0.11% | 1.27% | 2.33% | Q3 2013 | Q1 2017 | 4 |
| OLK | OLINK HLDG AB | 4 | 4 | 0.47% | 1.08% | 1.71% | Q1 2021 | Q4 2021 | 4 |
| OPHT | OPHTHOTECH CORP | 4 | 4 | 0.73% | 1.06% | 1.76% | Q4 2015 | Q3 2016 | 4 |
| BHVN | BIOHAVEN PHARMACTL | 2 | 1 | 0.02% | 1.04% | 2.23% | Q1 2019 | Q2 2022 | 4 |
| MRVI | MARAVAI LIFESCIENCES H... | 3 | 1 | 0.51% | 0.92% | 1.93% | Q4 2020 | Q2 2022 | 4 |
| EVHC | ENVISION HEALTHCARE | 4 | 4 | 0.66% | 0.84% | 0.91% | Q4 2016 | Q3 2017 | 4 |
| CTIC | CTI BIOPHARMA CORP | 3 | 1 | 0.01% | 0.82% | 1.14% | Q3 2018 | Q1 2023 | 4 |
| PCVX | VAXCYTE INC | 4 | 4 | 0.43% | 0.77% | 1.20% | Q4 2022 | Q3 2023 | 4 |
| FRLN | FREELINE THERAPEUTICS ... | 4 | 4 | 0.42% | 0.75% | 1.13% | Q3 2020 | Q2 2021 | 4 |
| GKOS | GLAUKOS CORP | 2 | 1 | 0.02% | 0.74% | 1.11% | Q1 2018 | Q3 2023 | 4 |
| STJ | ST JUDE MEDICAL INC | 4 | 4 | 0.00% | 0.74% | 1.05% | Q2 2015 | Q1 2016 | 4 |
| COO | COOPER COS INC | 3 | 1 | 0.20% | 0.69% | 1.01% | Q2 2020 | Q3 2021 | 4 |
| ONCE | SPARK THERAPEUTICS | 3 | 1 | 0.05% | 0.65% | 1.34% | Q2 2017 | Q1 2019 | 4 |
| ALT | ALTIMMUNE INC | 4 | 4 | 0.35% | 0.63% | 1.09% | Q2 2022 | Q1 2023 | 4 |
| BEAM | BEAM THERAPEUTICS | 4 | 4 | 0.34% | 0.45% | 0.62% | Q3 2022 | Q2 2023 | 4 |
| MASS | 908 DEVICES INC | 4 | 4 | 0.17% | 0.43% | 0.55% | Q3 2021 | Q2 2022 | 4 |
| SCAI | SURGICAL CARE AFFILIATES | 4 | 4 | 0.18% | 0.41% | 0.50% | Q1 2016 | Q4 2016 | 4 |
| IOVA | IOVANCE BIOTHERAPEUTIC... | 1 | 1 | 0.02% | 0.40% | 0.87% | Q3 2018 | Q3 2023 | 4 |
| ZSPH | ZS PHARMA INC | 4 | 4 | 0.09% | 0.40% | 1.02% | Q4 2014 | Q3 2015 | 4 |
| XBI | SPDR SER TR | 4 | 4 | 0.25% | 0.37% | 0.64% | Q4 2022 | Q3 2023 | 4 |
| SRRK | SCHOLAR ROCK HLDG | 4 | 4 | 0.21% | 0.30% | 0.43% | Q4 2022 | Q3 2023 | 4 |
| BCAB | BIOATLA INC | 4 | 4 | 0.22% | 0.25% | 0.28% | Q4 2022 | Q3 2023 | 4 |
| INGN | INOGEN INC | 4 | 4 | 0.19% | 0.24% | 0.29% | Q1 2014 | Q4 2014 | 4 |
| AVEO | AVEO PHARMACEUTICALS INC | 4 | 4 | 0.01% | 0.15% | 0.47% | Q2 2020 | Q1 2021 | 4 |
| HCM | HUTCHISON CHINA MEDITECH | 4 | 4 | 0.08% | 0.10% | 0.12% | Q3 2018 | Q2 2019 | 4 |
| TRILLIUM THERAPEUTICS | 4 | 4 | 0.06% | 0.10% | 0.16% | Q4 2016 | Q3 2017 | 4 | |
| IPXL | IMPAX LABS INC | 4 | 4 | 0.07% | 0.08% | 0.10% | Q1 2015 | Q4 2015 | 4 |
| EGRX | EAGLE PHARMACEUTICALS | 4 | 4 | 0.04% | 0.08% | 0.10% | Q1 2015 | Q4 2015 | 4 |
| DEPO | DEPOMED INC | 4 | 4 | 0.05% | 0.06% | 0.07% | Q1 2015 | Q4 2015 | 4 |
| KALV | KALVISTA PHARMACEUTICALS | 4 | 4 | 0.04% | 0.05% | 0.06% | Q3 2018 | Q2 2019 | 4 |
| EBIO | ELEVEN BIOTHERAPEUTICS | 3 | 1 | 0.03% | 0.05% | 0.06% | Q1 2014 | Q1 2015 | 4 |
| ROIVANT SCIENCES LTD | 4 | 4 | 0.03% | 0.04% | 0.07% | Q4 2022 | Q3 2023 | 4 | |
| PCRX | PACIRA PHARMACEUTICALS | 3 | 1 | 0.03% | 0.04% | 0.05% | Q1 2015 | Q2 2020 | 4 |
| CBPO | CHINA BIOLOGIC PROD | 4 | 4 | 0.03% | 0.04% | 0.06% | Q3 2015 | Q2 2016 | 4 |
| AFMD | AFFIMED N V | 4 | 4 | 0.02% | 0.04% | 0.06% | Q2 2021 | Q1 2022 | 4 |
| MYOK | MYOKARDIA INC | 2 | 1 | 0.02% | 0.04% | 0.07% | Q3 2018 | Q2 2020 | 4 |
| CBM | CAMBREX CORP | 4 | 4 | 0.02% | 0.03% | 0.05% | Q1 2015 | Q4 2015 | 4 |
| ACRX | ACELRX PHARMACEUTICALS | 4 | 4 | 0.02% | 0.03% | 0.03% | Q3 2018 | Q2 2019 | 4 |
| RVNC | REVANCE THERAPEUTICS | 4 | 4 | 0.02% | 0.02% | 0.03% | Q3 2018 | Q2 2019 | 4 |
| KURA | KURA ONCOLOGY INC | 4 | 4 | 0.02% | 0.02% | 0.03% | Q3 2018 | Q2 2019 | 4 |
| ATRS | ANTARES PHARMA INC | 4 | 4 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| CTMX | CYTOMX THERAPEUTICS | 4 | 4 | 0.01% | 0.02% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| BLRX | BIOLINERX LTD | 4 | 4 | 0.01% | 0.01% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| AGLE | AEGLEA BIOTHERAPEUTICS | 4 | 4 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q2 2019 | 4 |
| ABEO | ABEONA THERAPEUTICS | 4 | 4 | 0.01% | 0.01% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| NABRIVA THERAPEUTICS | 4 | 4 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q2 2019 | 4 | |
| MRNS | MARINUS PHARMACUTCLS | 4 | 4 | 0.01% | 0.01% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| CLSD | CLEARSIDE BIOMEDICAL | 4 | 4 | 0.00% | 0.01% | 0.02% | Q3 2018 | Q2 2019 | 4 |
| MINERALYS THERAPEUTI | 3 | 3 | 1.56% | 1.72% | 1.85% | Q1 2023 | Q3 2023 | 3 | |
| ADPTQ | ADEPTUS HEALTH INC | 3 | 3 | 0.44% | 1.64% | 3.30% | Q4 2015 | Q2 2016 | 3 |
| ISIS | ISIS PHARMACEUTICALS | 3 | 3 | 0.80% | 1.49% | 2.10% | Q3 2013 | Q1 2014 | 3 |
| OSH | OAK STR HEALTH INC | 3 | 3 | 1.08% | 1.35% | 1.52% | Q4 2020 | Q2 2021 | 3 |
| RVMD | REVOLUTION MEDICINES INC | 2 | 1 | 0.77% | 1.25% | 1.89% | Q3 2020 | Q3 2023 | 3 |
| IDXX | IDEXX LABS INC | 3 | 3 | 0.39% | 1.15% | 1.67% | Q2 2020 | Q4 2020 | 3 |
| ACCD | ACCOLADE INC | 3 | 3 | 0.74% | 1.12% | 1.62% | Q1 2021 | Q3 2021 | 3 |
| CNMD | CONMED CORP | 2 | 1 | 0.03% | 1.10% | 2.24% | Q2 2020 | Q3 2023 | 3 |
| KITE | KITE PHARMA INC | 3 | 3 | 0.58% | 1.02% | 1.85% | Q3 2016 | Q1 2017 | 3 |
| PCYC | PHARMACYCLICS INC | 3 | 3 | 0.77% | 1.01% | 1.14% | Q2 2013 | Q4 2013 | 3 |
| VERA | VERA THERAPEUTICS | 3 | 3 | 0.90% | 0.93% | 0.95% | Q1 2023 | Q3 2023 | 3 |
| FTSV | FORTY SEVEN INC | 3 | 3 | 0.83% | 0.88% | 0.91% | Q1 2019 | Q3 2019 | 3 |
| GRTX | GALERA THERAPEUTIC | 3 | 3 | 0.48% | 0.85% | 1.04% | Q4 2022 | Q2 2023 | 3 |
| NKTX | NKARTA INC | 3 | 3 | 0.42% | 0.79% | 1.05% | Q1 2021 | Q3 2021 | 3 |
| AIMT | AIMMUNE THERAPEUTICS | 3 | 3 | 0.64% | 0.78% | 0.92% | Q3 2015 | Q1 2016 | 3 |
| QTRX | QUANTERIX CORP | 3 | 3 | 0.48% | 0.73% | 1.08% | Q1 2021 | Q3 2021 | 3 |
| MMSI | MERIT MEDICAL SYS | 2 | 1 | 0.04% | 0.72% | 1.06% | Q2 2020 | Q3 2023 | 3 |
| CARA | CARA THERAPEUTICS | 3 | 3 | 0.36% | 0.64% | 0.87% | Q3 2015 | Q1 2016 | 3 |
| TMH | TEAM HEALTH HOLDINGS | 3 | 3 | 0.54% | 0.63% | 0.74% | Q1 2016 | Q3 2016 | 3 |
| VAR | VARIAN MED SYS INC | 1 | 1 | 0.00% | 0.61% | 1.68% | Q2 2013 | Q2 2020 | 3 |
| AMSG | AMSURG CORP | 3 | 3 | 0.35% | 0.59% | 0.77% | Q1 2016 | Q3 2016 | 3 |
| NVRO | NEVRO CORP | 2 | 1 | 0.06% | 0.58% | 0.93% | Q1 2018 | Q2 2020 | 3 |
| GLYC | GLYCOMIMETICS INC | 2 | 1 | 0.03% | 0.55% | 0.82% | Q1 2014 | Q2 2019 | 3 |
| NITE | NIGHTSTAR THERAPEUTICS | 3 | 3 | 0.37% | 0.53% | 0.71% | Q3 2018 | Q1 2019 | 3 |
| CRL | CHARLES RIV LABS INTL INC | 2 | 1 | 0.12% | 0.53% | 0.78% | Q2 2020 | Q3 2021 | 3 |
| NEO | NEOGENOMICS INC | 2 | 1 | 0.04% | 0.42% | 0.76% | Q2 2020 | Q4 2021 | 3 |
| BOLT | BOLT BIOTHERAPEUTICS INC | 3 | 3 | 0.12% | 0.41% | 0.80% | Q1 2021 | Q3 2021 | 3 |
| XRAY | DENTSPLY SIRONA INC | 2 | 1 | 0.14% | 0.41% | 0.55% | Q2 2020 | Q3 2021 | 3 |
| PTI | PROTEOSTASIS THERAPEUTICS | 2 | 1 | 0.22% | 0.41% | 0.70% | Q4 2017 | Q1 2019 | 3 |
| WCG | WELLCARE HEALTH PLAN | 3 | 3 | 0.06% | 0.40% | 0.62% | Q3 2018 | Q1 2019 | 3 |
| ANNX | ANNEXON INC | 3 | 3 | 0.24% | 0.35% | 0.41% | Q1 2023 | Q3 2023 | 3 |
| ONCR | ONCORUS INC | 3 | 3 | 0.28% | 0.34% | 0.37% | Q1 2021 | Q3 2021 | 3 |
| NCNA | NUCANA PLC | 3 | 3 | 0.24% | 0.33% | 0.42% | Q3 2020 | Q1 2021 | 3 |
| PMVP | PMV PHARMACEUTICALS | 3 | 3 | 0.23% | 0.31% | 0.36% | Q1 2023 | Q3 2023 | 3 |
| MGNX | MACROGENICS INC | 2 | 1 | 0.26% | 0.31% | 0.35% | Q4 2022 | Q3 2023 | 3 |
| RAIN | RAIN THERAPEUTICS INC | 2 | 1 | 0.02% | 0.29% | 0.82% | Q2 2021 | Q1 2023 | 3 |
| URGN | UROGEN PHARMA LTD | 3 | 3 | 0.27% | 0.28% | 0.29% | Q1 2019 | Q3 2019 | 3 |
| JASPER THERAPEUTICS INC | 3 | 3 | 0.06% | 0.26% | 0.42% | Q1 2022 | Q3 2022 | 3 | |
| PROCAPS GROUP SA | 3 | 3 | 0.16% | 0.24% | 0.32% | Q3 2021 | Q1 2022 | 3 | |
| ALLK | ALLAKOS INC | 2 | 1 | 0.02% | 0.23% | 0.34% | Q2 2020 | Q3 2023 | 3 |
| STEVANATO GROUP SPA | 3 | 3 | 0.07% | 0.19% | 0.45% | Q3 2021 | Q1 2022 | 3 | |
| PHAS | PHASEBIO PHARMACEUTICALS | 3 | 3 | 0.14% | 0.19% | 0.28% | Q2 2019 | Q4 2019 | 3 |
| CBAY | CYMABAY THERAPEUTICS | 2 | 1 | 0.02% | 0.18% | 0.31% | Q3 2014 | Q3 2018 | 3 |
| FDMT | 4D MOLECULAR THERAPEUT... | 2 | 1 | 0.02% | 0.17% | 0.26% | Q4 2020 | Q1 2023 | 3 |
| HZNP | HORIZON PHARMA | 3 | 3 | 0.05% | 0.07% | 0.10% | Q1 2015 | Q3 2015 | 3 |
| RNA | PROSENSA HLDGS | 3 | 3 | 0.03% | 0.06% | 0.09% | Q2 2014 | Q4 2014 | 3 |
| DERM | DERMIRA INC | 3 | 3 | 0.04% | 0.05% | 0.07% | Q3 2018 | Q1 2019 | 3 |
| VIR | VIR BIOTECHNOLOGY INC | 1 | 1 | 0.02% | 0.03% | 0.04% | Q2 2020 | Q2 2022 | 3 |
| ANTH | ANTHERA PHARMACEUTICALS | 3 | 3 | 0.02% | 0.03% | 0.03% | Q1 2014 | Q3 2014 | 3 |
| QTNT | QUOTIENT LTD | 3 | 3 | 0.01% | 0.02% | 0.02% | Q3 2018 | Q1 2019 | 3 |
| PTGX | PROTAGONIST THERAPEUTICS | 3 | 3 | 0.01% | 0.01% | 0.02% | Q4 2018 | Q2 2019 | 3 |
| SMMT | SUMMIT THERAPEUTICS | 3 | 3 | 0.01% | 0.01% | 0.02% | Q1 2023 | Q3 2023 | 3 |
| CDTX | CIDARA THERAPEUTICS | 3 | 3 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q1 2019 | 3 |
| ACT | ACTAVIS INC | 2 | 2 | 1.40% | 2.80% | 4.20% | Q2 2013 | Q3 2013 | 2 |
| ARIA | ARIAD PHARMACEUTICAL | 2 | 2 | 2.66% | 2.70% | 2.74% | Q2 2013 | Q3 2013 | 2 |
| PRGO | PERRIGO CO | 2 | 2 | 1.37% | 1.75% | 2.12% | Q2 2013 | Q3 2013 | 2 |
| AFIB | ACUTUS MED INC | 2 | 2 | 1.36% | 1.68% | 1.99% | Q3 2020 | Q4 2020 | 2 |
| AMWL | AMERICAN WELL CORP | 2 | 2 | 1.29% | 1.42% | 1.54% | Q3 2020 | Q4 2020 | 2 |
| MOONLAKE IMMUNOTHERA | 2 | 2 | 1.09% | 1.33% | 1.57% | Q2 2023 | Q3 2023 | 2 | |
| AET | AETNA INC | 1 | 1 | 0.02% | 1.26% | 2.50% | Q4 2016 | Q3 2018 | 2 |
| AVAH | AVEANNA HEALTHCARE HLD... | 2 | 2 | 0.78% | 1.22% | 1.66% | Q2 2021 | Q3 2021 | 2 |
| VOR | VOR BIOPHARMA INC | 2 | 2 | 0.61% | 1.18% | 1.75% | Q1 2021 | Q2 2021 | 2 |
| NXTC | NEXTCURE INC | 2 | 2 | 0.70% | 0.88% | 1.05% | Q4 2019 | Q1 2020 | 2 |
| 2SEVENTY BIO INC | 2 | 2 | 0.78% | 0.86% | 0.93% | Q1 2023 | Q2 2023 | 2 | |
| HARP | HARPOON THERAPEUTICS INC | 2 | 2 | 0.65% | 0.83% | 1.00% | Q1 2021 | Q2 2021 | 2 |
| EPIX | ESSA PHARMA INC | 2 | 2 | 0.77% | 0.79% | 0.82% | Q1 2021 | Q2 2021 | 2 |
| VPHM | VIROPHARMA INC | 2 | 2 | 0.47% | 0.76% | 1.05% | Q2 2013 | Q3 2013 | 2 |
| NPCE | NEUROPACE INC | 2 | 2 | 0.59% | 0.75% | 0.91% | Q2 2021 | Q3 2021 | 2 |
| BLI | BERKELEY LTS INC | 2 | 2 | 0.69% | 0.74% | 0.80% | Q3 2021 | Q4 2021 | 2 |
| PSTX | POSEIDA THERAPEUTICS INC | 2 | 2 | 0.65% | 0.73% | 0.80% | Q3 2020 | Q4 2020 | 2 |
| FRX | FOREST LABS INC | 1 | 1 | 0.34% | 0.68% | 1.02% | Q2 2013 | Q1 2014 | 2 |
| OCUL | OCULAR THERAPEUTIX | 2 | 2 | 0.59% | 0.64% | 0.69% | Q2 2023 | Q3 2023 | 2 |
| PGNY | PROGYNY INC | 1 | 1 | 0.37% | 0.58% | 0.80% | Q3 2021 | Q3 2023 | 2 |
| TELA | TELA BIO INC | 2 | 2 | 0.30% | 0.56% | 0.82% | Q2 2023 | Q3 2023 | 2 |
| DNAY | CODEX DNA INC | 2 | 2 | 0.14% | 0.53% | 0.92% | Q2 2021 | Q3 2021 | 2 |
| BETTER THERAPEUTICS INC | 2 | 2 | 0.31% | 0.50% | 0.68% | Q4 2021 | Q1 2022 | 2 | |
| TECH | BIO-TECHNE CORP | 1 | 1 | 0.14% | 0.42% | 0.71% | Q2 2020 | Q3 2021 | 2 |
| FNCH | FINCH THERAPEUTICS GRO... | 2 | 2 | 0.34% | 0.41% | 0.48% | Q1 2021 | Q2 2021 | 2 |
| VIRX | VIRACTA THERAPEUTICS INC | 2 | 2 | 0.36% | 0.41% | 0.45% | Q1 2021 | Q2 2021 | 2 |
| SIGHT SCIENCES INC | 2 | 2 | 0.35% | 0.40% | 0.45% | Q4 2021 | Q1 2022 | 2 | |
| NVAX | NOVAVAX INC | 2 | 2 | 0.10% | 0.39% | 0.68% | Q1 2016 | Q2 2016 | 2 |
| EBS | EMERGENT BIOSOLUTNS | 2 | 2 | 0.05% | 0.38% | 0.71% | Q2 2020 | Q3 2020 | 2 |
| TIL | INSTIL BIO INC | 2 | 2 | 0.03% | 0.37% | 0.72% | Q1 2021 | Q2 2021 | 2 |
| EYPT | EYEPOINT PHARMA | 2 | 2 | 0.27% | 0.36% | 0.45% | Q2 2023 | Q3 2023 | 2 |
| AMED | AMEDISYS INC | 2 | 2 | 0.29% | 0.30% | 0.32% | Q2 2020 | Q3 2020 | 2 |
| STRO | SUTRO BIOPHARMA IN | 2 | 2 | 0.29% | 0.30% | 0.31% | Q2 2023 | Q3 2023 | 2 |
| CSTL | CASTLE BIOSCIENCES INC | 2 | 2 | 0.08% | 0.29% | 0.50% | Q2 2020 | Q3 2020 | 2 |
| PNT | POINT BIOPHARMA GBL | 2 | 2 | 0.26% | 0.26% | 0.26% | Q4 2022 | Q1 2023 | 2 |
| THOR | THORATEC LABS CORP | 1 | 1 | 0.00% | 0.22% | 0.44% | Q2 2013 | Q2 2015 | 2 |
| CYRX | CRYOPORT INC | 2 | 2 | 0.16% | 0.21% | 0.26% | Q1 2021 | Q2 2021 | 2 |
| SONENDO INC | 2 | 2 | 0.08% | 0.19% | 0.30% | Q4 2021 | Q1 2022 | 2 | |
| SHC | SOTERA HEALTH CO | 2 | 2 | 0.14% | 0.16% | 0.17% | Q4 2020 | Q1 2021 | 2 |
| CAH | CARDINAL HEALTH INC | 1 | 1 | 0.04% | 0.13% | 0.22% | Q3 2018 | Q2 2020 | 2 |
| TBPH | THERAVANCE BIOPHARMA | 1 | 1 | 0.03% | 0.12% | 0.21% | Q2 2014 | Q3 2018 | 2 |
| PRONAI THERAPEUTICS | 1 | 1 | 0.04% | 0.05% | 0.07% | Q1 2016 | Q4 2016 | 2 | |
| EARS | AURIS MED HLDG AG | 2 | 2 | 0.05% | 0.05% | 0.06% | Q1 2015 | Q2 2015 | 2 |
| BLUE | BLUEBIRD BIO INC | 1 | 1 | 0.05% | 0.05% | 0.06% | Q3 2018 | Q2 2020 | 2 |
| CERS | CERUS CORP | 2 | 2 | 0.04% | 0.04% | 0.05% | Q3 2018 | Q4 2018 | 2 |
| HRTX | HERON THERAPEUTICS | 1 | 1 | 0.02% | 0.03% | 0.05% | Q3 2018 | Q2 2020 | 2 |
| KANG | IKANG HEALTHCARE GROUP | 2 | 2 | 0.02% | 0.03% | 0.03% | Q3 2018 | Q4 2018 | 2 |
| FPRX | FIVE PRIME THERAPEUTICS | 1 | 1 | 0.02% | 0.02% | 0.03% | Q1 2014 | Q3 2018 | 2 |
| KOD | KODIAK SCIENCES INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q4 2020 | 2 |
| GTH | GENETRON HLDGS LTD | 2 | 2 | 0.02% | 0.02% | 0.02% | Q1 2021 | Q2 2021 | 2 |
| COGT | UNUM THERAPEUTICS INC | 2 | 2 | 0.02% | 0.02% | 0.02% | Q1 2021 | Q2 2021 | 2 |
| AMRX | AMNEAL PHARMACEUTICALS | 1 | 1 | 0.01% | 0.01% | 0.02% | Q3 2018 | Q2 2020 | 2 |
| BAX | BAXTER INTL INC | 1 | 1 | 0.00% | 0.01% | 0.03% | Q2 2015 | Q3 2018 | 2 |
| PLX | PROTALIX BIOTHERAPEUTICS | 2 | 2 | 0.00% | 0.01% | 0.01% | Q3 2018 | Q4 2018 | 2 |
| ONXX | ONYX PHARMACEUTICALS | 1 | 1 | 3.48% | 3.48% | 3.48% | Q2 2013 | Q2 2013 | 1 |
| AEGR | AEGERION PHARMACEU | 1 | 1 | 1.77% | 1.77% | 1.77% | Q1 2014 | Q1 2014 | 1 |
| BHG | BRIGHT HEALTH GROUP INC | 1 | 1 | 1.27% | 1.27% | 1.27% | Q2 2021 | Q2 2021 | 1 |
| CINCOR PHARMA INC | 1 | 1 | 1.26% | 1.26% | 1.26% | Q3 2022 | Q3 2022 | 1 | |
| DEFINITIVE HEALTHCARE ... | 1 | 1 | 1.17% | 1.17% | 1.17% | Q4 2021 | Q4 2021 | 1 | |
| GDRX | GOODRX HLDGS INC | 1 | 1 | 1.10% | 1.10% | 1.10% | Q3 2023 | Q3 2023 | 1 |
| FMTX | FORMA THERAPEUTICS | 1 | 1 | 1.01% | 1.01% | 1.01% | Q2 2020 | Q2 2020 | 1 |
| MDT | MEDTRONIC INC | 1 | 1 | 1.00% | 1.00% | 1.00% | Q4 2014 | Q4 2014 | 1 |
| INNV | INNOVAGE HLDG CORP | 1 | 1 | 0.94% | 0.94% | 0.94% | Q1 2021 | Q1 2021 | 1 |
| SGFY | SIGNIFY HEALTH INC | 1 | 1 | 0.86% | 0.86% | 0.86% | Q3 2022 | Q3 2022 | 1 |
| DYN | DYNE THERAPEUTICS INC | 1 | 1 | 0.82% | 0.82% | 0.82% | Q3 2020 | Q3 2020 | 1 |
| RAPID MICRO BIOSYSTEMS... | 1 | 1 | 0.78% | 0.78% | 0.78% | Q3 2021 | Q3 2021 | 1 | |
| SGTX | SIGILON THERAPEUTICS INC | 1 | 1 | 0.76% | 0.76% | 0.76% | Q4 2020 | Q4 2020 | 1 |
| TSHA | TAYSHA GENE THERAPIES INC | 1 | 1 | 0.72% | 0.72% | 0.72% | Q3 2020 | Q3 2020 | 1 |
| LUNG | PULMONX CORP | 1 | 1 | 0.70% | 0.70% | 0.70% | Q1 2021 | Q1 2021 | 1 |
| ACELYRIN INC | 1 | 1 | 0.70% | 0.70% | 0.70% | Q2 2023 | Q2 2023 | 1 | |
| DOCGO INC | 1 | 1 | 0.68% | 0.68% | 0.68% | Q3 2023 | Q3 2023 | 1 | |
| EVAC | EDWARDS LIFESCIENCE | 1 | 1 | 0.66% | 0.66% | 0.66% | Q3 2013 | Q3 2013 | 1 |
| ATEC | ALPHATEC HOLDINGS IN | 1 | 1 | 0.62% | 0.62% | 0.62% | Q3 2023 | Q3 2023 | 1 |
| VENTYX BIOSCIENCES I | 1 | 1 | 0.60% | 0.60% | 0.60% | Q3 2023 | Q3 2023 | 1 | |
| CYTEK BIOSCIENCES INC | 1 | 1 | 0.58% | 0.58% | 0.58% | Q3 2021 | Q3 2021 | 1 | |
| TOCA | TOCAGEN INC | 1 | 1 | 0.54% | 0.54% | 0.54% | Q2 2019 | Q2 2019 | 1 |
| SQNM | SEQUENOM INC | 1 | 1 | 0.51% | 0.51% | 0.51% | Q2 2013 | Q2 2013 | 1 |
| TURNSTONE BIOLOGICS | 1 | 1 | 0.40% | 0.40% | 0.40% | Q3 2023 | Q3 2023 | 1 | |
| TLIS | TALIS BIOMEDICAL CORP | 1 | 1 | 0.40% | 0.40% | 0.40% | Q1 2021 | Q1 2021 | 1 |
| MCAD | MOUNTAIN CREST ACQUSTN... | 1 | 1 | 0.39% | 0.39% | 0.39% | Q3 2021 | Q3 2021 | 1 |
| SEER | SEER INC | 1 | 1 | 0.38% | 0.38% | 0.38% | Q4 2020 | Q4 2020 | 1 |
| VCEL | VERICEL CORP | 1 | 1 | 0.36% | 0.36% | 0.36% | Q4 2019 | Q4 2019 | 1 |
| EQRX INC | 1 | 1 | 0.35% | 0.35% | 0.35% | Q2 2023 | Q2 2023 | 1 | |
| VERASTEM INC | 1 | 1 | 0.32% | 0.32% | 0.32% | Q3 2023 | Q3 2023 | 1 | |
| AMRN | AMARIN CORP PLC | 1 | 1 | 0.31% | 0.31% | 0.31% | Q2 2013 | Q2 2013 | 1 |
| TKNO | ALPHA TEKNOVA INC | 1 | 1 | 0.30% | 0.30% | 0.30% | Q2 2021 | Q2 2021 | 1 |
| DOCS | DOXIMITY INC | 1 | 1 | 0.29% | 0.29% | 0.29% | Q4 2021 | Q4 2021 | 1 |
| ZYMEWORKS INC | 1 | 1 | 0.29% | 0.29% | 0.29% | Q4 2022 | Q4 2022 | 1 | |
| BYSI | BEYONDSPRING INC | 1 | 1 | 0.28% | 0.28% | 0.28% | Q3 2021 | Q3 2021 | 1 |
| BABYLON HOLDINGS LTD | 1 | 1 | 0.28% | 0.28% | 0.28% | Q4 2021 | Q4 2021 | 1 | |
| MRSN | MERSANA THERAPEUTI | 1 | 1 | 0.27% | 0.27% | 0.27% | Q1 2023 | Q1 2023 | 1 |
| ANAB | ANAPTYSBIO INC | 1 | 1 | 0.27% | 0.27% | 0.27% | Q2 2018 | Q2 2018 | 1 |
| BTAI | BIOXCEL THERAPEUTI | 1 | 1 | 0.25% | 0.25% | 0.25% | Q4 2022 | Q4 2022 | 1 |
| GLUE | MONTE ROSA THERAPEUTIC... | 1 | 1 | 0.24% | 0.24% | 0.24% | Q2 2021 | Q2 2021 | 1 |
| WST | WEST PHARMACEUT SVS | 1 | 1 | 0.24% | 0.24% | 0.24% | Q2 2020 | Q2 2020 | 1 |
| PSNL | PERSONALIS INC | 1 | 1 | 0.22% | 0.22% | 0.22% | Q1 2021 | Q1 2021 | 1 |
| DGX | QUEST DIAGNOSTICS | 1 | 1 | 0.22% | 0.22% | 0.22% | Q2 2020 | Q2 2020 | 1 |
| VSAR | VERSARTIS INC | 1 | 1 | 0.20% | 0.20% | 0.20% | Q2 2017 | Q2 2017 | 1 |
| PBYI | PUMA BIOTECHNOLOGY | 1 | 1 | 0.19% | 0.19% | 0.19% | Q4 2017 | Q4 2017 | 1 |
| STE | STERIS PLC | 1 | 1 | 0.18% | 0.18% | 0.18% | Q2 2020 | Q2 2020 | 1 |
| LATN | UNION ACQUISITION CORP II | 1 | 1 | 0.18% | 0.18% | 0.18% | Q2 2021 | Q2 2021 | 1 |
| PKI | PERKINELMER INC | 1 | 1 | 0.15% | 0.15% | 0.15% | Q2 2020 | Q2 2020 | 1 |
| REGENXBIO INC | 1 | 1 | 0.13% | 0.13% | 0.13% | Q4 2015 | Q4 2015 | 1 | |
| BIO | BIO RAD LABS INC | 1 | 1 | 0.13% | 0.13% | 0.13% | Q2 2020 | Q2 2020 | 1 |
| ELAN | ELANCO ANIMAL HEALTH | 1 | 1 | 0.12% | 0.12% | 0.12% | Q2 2020 | Q2 2020 | 1 |
| ANAC | ANACOR PHARMACEUTI | 1 | 1 | 0.12% | 0.12% | 0.12% | Q1 2016 | Q1 2016 | 1 |
| HSIC | HENRY SCHEIN INC | 1 | 1 | 0.12% | 0.12% | 0.12% | Q2 2020 | Q2 2020 | 1 |
| QDEL | QUIDEL CORP | 1 | 1 | 0.12% | 0.12% | 0.12% | Q2 2020 | Q2 2020 | 1 |
| AVTR | AVANTOR INC | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2020 | Q2 2020 | 1 |
| CHE | CHEMED CORP NEW | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2020 | Q2 2020 | 1 |
| AMBI | AMBIT BIOSCIENCES | 1 | 1 | 0.10% | 0.10% | 0.10% | Q3 2014 | Q3 2014 | 1 |
| DVA | DAVITA INC | 1 | 1 | 0.09% | 0.09% | 0.09% | Q2 2020 | Q2 2020 | 1 |
| MREO | MEREO BIOPHARMA GR | 1 | 1 | 0.09% | 0.09% | 0.09% | Q2 2022 | Q2 2022 | 1 |
| EHC | ENCOMPASS HEALTH COR | 1 | 1 | 0.09% | 0.09% | 0.09% | Q2 2020 | Q2 2020 | 1 |
| RNA | AVIDITY BIOSCIENCE | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2020 | Q2 2020 | 1 |
| PEN | PENUMBRA INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2020 | Q2 2020 | 1 |
| LHCG | LHC GROUP INC | 1 | 1 | 0.07% | 0.07% | 0.07% | Q2 2020 | Q2 2020 | 1 |
| EDWARDS LIFESCIENCES | 1 | 1 | 0.07% | 0.07% | 0.07% | Q3 2018 | Q3 2018 | 1 | |
| HAE | HAEMONETICS CORP | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2020 | Q2 2020 | 1 |
| MCRB | SERES THERAPEUTICS | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2016 | Q2 2016 | 1 |
| VERALTO CORPORATION | 1 | 1 | 0.06% | 0.06% | 0.06% | Q3 2023 | Q3 2023 | 1 | |
| BRKR | BRUKER CORP | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2020 | Q2 2020 | 1 |
| NEOG | NEOGEN CORP | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2020 | Q2 2020 | 1 |
| ATHN | ATHENAHEALTH INC | 1 | 1 | 0.05% | 0.05% | 0.05% | Q3 2018 | Q3 2018 | 1 |
| ICUI | ICU MED INC | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2020 | Q2 2020 | 1 |
| PRQR | PROQR THRAPEUTICS | 1 | 1 | 0.05% | 0.05% | 0.05% | Q3 2014 | Q3 2014 | 1 |
| GMED | GLOBUS MED INC | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2020 | Q2 2020 | 1 |
| NVST | ENVISTA HLDGS CORP | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2020 | Q2 2020 | 1 |
| TPST | TEMPEST THERAPEUTICS | 1 | 1 | 0.05% | 0.05% | 0.05% | Q2 2023 | Q2 2023 | 1 |
| OMCL | OMNICELL INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q2 2020 | Q2 2020 | 1 |
| AKCA | AKCEA THERAPEUTICS | 1 | 1 | 0.04% | 0.04% | 0.04% | Q3 2018 | Q3 2018 | 1 |
| RIGL | RIGEL PHARMACEUTICALS | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| ITGR | INTEGER HLDGS CORP | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| LIVN | LIVANOVA PLC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| AXSM | AXSOME THERAPEUTIC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| MDCO | MEDICINES CO | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| GSK | GLAXOSMITHKLINE PLC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| RTRX | RETROPHIN INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| ENSG | ENSIGN GROUP INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| ALLO | ALLOGENE THERAPEUT | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| STE | STERIS PLC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| PBH | PRESTIGE CONSUMER HE | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| WBA | WALGREENS BOOTS ALLIANCE | 1 | 1 | 0.03% | 0.03% | 0.03% | Q3 2018 | Q3 2018 | 1 |
| PDCO | PATTERSON COMPANIES | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| HCSG | HEALTHCARE SVCS GRP | 1 | 1 | 0.03% | 0.03% | 0.03% | Q2 2020 | Q2 2020 | 1 |
| LPTN | LPATH INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2014 | Q1 2014 | 1 |
| ECYT | ENDOCYTE INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q3 2018 | 1 |
| XNCR | XENCOR INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| CMD | CANTEL MEDICAL CORP | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| TKMR | TEKMIRA PHARMACEU | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2014 | Q1 2014 | 1 |
| EDIT | EDITAS MEDICINE INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| LGND | LIGAND PHARMACEUTIC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| CORT | CORCEPT THERAPEUTICS | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| MGLN | MAGELLAN HEALTH INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| SEM | SELECT MED HLDGS | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| GTHX | G1 THERAPEUTICS | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q3 2018 | 1 |
| BEAT | BIOTELEMETRY INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| ZGNX | ZOGENIX INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| OSUR | ORASURE TECHNOLOGIES | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q3 2018 | 1 |
| AVNS | AVANOS MEDICAL INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| EPZM | EPIZYME INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| MD | MEDNAX INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| OPK | OPKO HEALTH INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| LMNX | LUMINEX CORP DEL | 1 | 1 | 0.02% | 0.02% | 0.02% | Q2 2020 | Q2 2020 | 1 |
| AQXP | AQUINOX PHARMACEUT | 1 | 1 | 0.02% | 0.02% | 0.02% | Q1 2014 | Q1 2014 | 1 |
| BDSI | BIODELIVERY SCIENCES | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q3 2018 | 1 |
| ADRO | ADURO BIOTECH INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2018 | Q3 2018 | 1 |
| PRTK | PARATEK PHARMACEUTICALS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| AVEO | AVEO PHARMACUTICALS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| PROTAGONIST THERAPEUTICS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 | |
| PGNX | PROGENICS PHARMACEUTICALS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| MYGN | MYRIAD GENETICS INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2020 | Q2 2020 | 1 |
| BKD | BROOKDALE SR LIVING | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2020 | Q2 2020 | 1 |
| AVDL | AVADEL PHARMACEUTICALS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| CNAT | CONATUS PHARMACEUTICALS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| PGEN | PRECIGEN INC | 1 | 1 | 0.01% | 0.01% | 0.01% | Q2 2020 | Q2 2020 | 1 |
| SLNO | SOLENO THERAPEUTICS | 1 | 1 | 0.01% | 0.01% | 0.01% | Q3 2018 | Q3 2018 | 1 |
| TXMD | THERAPEUTICSMD INC | 1 | 1 | 0.00% | 0.00% | 0.00% | Q2 2020 | Q2 2020 | 1 |
| GNCA | GENOCEA BIOSCIENCES | 1 | 1 | 0.00% | 0.00% | 0.00% | Q3 2018 | Q3 2018 | 1 |
| SNSS | SUNESIS PHARMACEUTICALS | 1 | 1 | 0.00% | 0.00% | 0.00% | Q3 2018 | Q3 2018 | 1 |
| AGRX | AGILE THERAPEUTICS | 1 | 1 | 0.00% | 0.00% | 0.00% | Q3 2018 | Q3 2018 | 1 |
| SPNC | SPECTRANETICS CORP | 1 | 1 | 0.00% | 0.00% | 0.00% | Q2 2015 | Q2 2015 | 1 |
Download | |||||||||
The securities at the top of the list , including BIOMARIN PHARMAC INC, PTC THERAPEUTICS INC, and DR REDDYS LABS LTD, are the highest-conviction holdings of SECTORAL ASSET MANAGEMENT INC.
The conviction is calculated by counting the number of quarters a security has been reported by SECTORAL ASSET MANAGEMENT INC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that SECTORAL ASSET MANAGEMENT INC owns currently or has owned in the past.